

## Product Data Sheet

Product Name: MEN 10376

Cat. No.: GC17547

### Chemical Properties

Cas. No. 135306-85-3

Chemical Name (3S,6S,9R,12R,15S,18S,21R)-9,15,18-tris((1H-indol-3-yl)methyl)-3,25-diamino-21-carbamoyl-6-(4-hydroxybenzyl)-12-isopropyl-4,7,10,13,16,19-hexaoxo-5,8,11,14,17,20-hexaazapentacosan-1-oic acid

SMILES O=C([C@@H](C(C)C)NC([C@@H](CC1=CNC2=CC=CC=C12)NC([C@H](CC(C=C3)=CC=C3O)NC([C@H](CC(O)=O)N)=O)=O)N[C@H](C(N[C@H](C(N[C@@H](C(N)=O)CCCCN)=O)CC4=CNC5=CC=CC=C45)=O)CC6=CNC7=CC=CC=C67

Formula C<sub>57</sub>H<sub>68</sub>N<sub>12</sub>O<sub>10</sub>

M.Wt 1081.24

Solubility Water : 1.43 mg/mL (1.20 mM)

Storage Desiccate at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure 

### Background

Men 10376 is a selective tachykinin NK-2 receptor antagonist, with a  $K_i$  of 4.4  $\mu$ M for rat small intestine NK-2 receptor.

Men 10376 is a selective tachykinin NK-2 receptor, with a  $K_i$  of 4.4  $\mu$ M, and shows low selectivity for NK-1 and NK-3 receptors ( $K_i$ , >10  $\mu$ M)[1]. Men 10376 shows pA<sub>2</sub>s of 5.66 and 8.08 for NK-1 (guinea-pig ileum) and NK-2 receptors (endothelium-deprived rabbit pulmonary artery). Men 10376 shows no effect on NK-3 receptor ( $K_i$ , >10  $\mu$ M)[2].

Men 10376 (1 and 3  $\mu$ mol/kg) antagonizes increase in bladder motility produced by the NK-2 receptor agonist in rats[2].

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

## Product Data Sheet

---

### References:

- [1]. Quartara L, et al. N-terminal truncated analogs of men 10376 as tachykinin NK-2 receptor antagonists. *Life Sci.* 1992;51(25):1929-36.
- [2]. Maggi CA, et al. In vivo evidence for tachykininergic transmission using a new NK-2 receptor-selective antagonist, MEN 10,376. *J Pharmacol Exp Ther.* 1991 Jun;257(3):1172-8.

***Caution: Product has not been fully validated for medical applications. For research use only.***

***Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com***

***Address: 10292 Central Ave. #205, Montclair, CA, USA***